How long does a dog live after a splenectomy for hemangiosarcoma? One honest answer.

The one number, and where it comes from

The most cited study on exactly this question followed 208 dogs with splenic hemangiosarcoma treated by removing the spleen. According to PubMed, the median survival time for the dogs treated with surgery alone was 1.6 months (Wendelburg et al., Journal of the American Veterinary Medical Association, 2015).

That is a hard number to read, and we are not going to soften it. But we are going to do something the uncited "1 to 3 months" ranges elsewhere cannot: tell you exactly what it means, and what it does not.

What a "median" actually means

This is the single most important idea on this page, and almost no one explains it. A median is not a prediction for your dog. It is the middle of a range. When the median is 1.6 months, it means that if you lined up all 208 dogs by how long they lived, the dog in the exact middle reached 1.6 months. Which means, by definition, half of the dogs lived longer than that, and some lived much longer.

Why does this matter so much? Because for the rest of your dog's care, you will be handed numbers, medians, response rates, one-year survival figures, and how you read them decides whether you spiral or make clear decisions. A median tells you the middle of what happened to a group. It never tells you where your dog will land.

Stage matters more than anything else

In that study of 208 dogs, one thing stood out above everything: clinical stage was the only factor significantly associated with how long a dog lived. Not age, not breed, not size. Stage.

Stage is a measure of how far the cancer has already spread by the time of surgery, and for hemangiosarcoma it is usually described in three levels:

This is why two dogs with "the same diagnosis" can face very different roads. It is also why the most useful question you can ask your oncologist is not "how long," but "what stage is my dog, and how did you determine it?" The answer to that shapes everything else, and it is knowable, through chest imaging, abdominal ultrasound, and the pathology report on the removed spleen.

Does chemotherapy help?

This is the next question almost every owner asks, and the honest answer from the same study is nuanced. Across the whole follow-up period, there was no statistically significant difference in survival between dogs that had surgery alone and dogs that had surgery plus chemotherapy. That sounds discouraging. But looking closer, during the first four months, chemotherapy did significantly prolong survival (a hazard ratio of 0.6 for any chemotherapy, and 0.4 for dogs receiving both conventional and metronomic protocols together).

Put plainly: chemotherapy appeared to help meaningfully in the early, most fragile window, and the combination of two chemotherapy styles looked better than either alone, but the authors were careful to call the overall benefit modest, not durable. It buys time for many dogs; it is not, on these numbers, a cure. Whether it is right for your dog, given the side effects, the cost, and the stage, is a real conversation to have with a veterinary oncologist, not a foregone conclusion in either direction.

What this means for your dog

• Ask for the stage, and how it was determined. It is the number that matters most, and it is knowable.
• Read the 1.6-month median as a midpoint, not a verdict. Half of dogs lived longer. Your dog is not a statistic.
• Weigh chemotherapy as a real but modest option, most helpful early, and reasonable to discuss both for and against.
• If any newer or personalized option interests you, protect the tumor sample now. How the removed spleen is stored decides what stays possible later. We wrote a short guide to preserving the tumor sample.

The honest part, including about us

You will read, on other sites, about vaccines and immunotherapies and new approaches for this cancer, and you may find your way to ours. So we want to be direct while the hard numbers above are still in front of you: no cancer vaccine, including the personalized ones we design, has published canine efficacy data measured against this splenectomy benchmark. The science is genuinely promising and worth pursuing, which is why we pursue it, and we cover the full landscape honestly in our vaccine scoreboard and the rest of the hemangiosarcoma guide. But nothing on the horizon changes the numbers on this page today, and anyone who tells you otherwise is selling something. You deserve the real figure first, which is why it leads this article.

A note on sources

The survival figures here come from one peer-reviewed study, cited by DOI, rather than from an uncited range: Wendelburg et al., JAVMA 2015, a retrospective series of 208 dogs. Survival statistics are population results and do not predict any individual dog's outcome. Numbers from a single study are a strong starting point for a conversation with your veterinarian, not a substitute for one.